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Pneumatosis coli (PC) is deﬁned as the presence of air in the
intestinal wall and is a signiﬁcant complication of gastro-
intestinal (GI) graft-versus-host disease (GVHD) following
hematopoietic cell transplantation (HCT).To better deﬁne
risk factors for the development of PC and its outcome, we
conducted a retrospective study in patients who developed
severe GI GVHD after allogeneic transplant.
From January 2005 to December 2010, 470 related and
unrelated HCT were realised at Maisonneuve-Rosemont
Hospital. Of this group, 103 patients (21.9%) developed grade
III to IV aGVHD. This study examines 91 of these 103 patients
(88%). 12 patients with grade III to IV aGVHD (11.6%) were
diagnosed with PC by tomodensitometry. This study
compares the clinical characteristics, treatment and evolu-
tion of these 12 patients with PC with the control group of 91
patients with severe GI GVHD without PC.
All patients (100%) who developed PC received oral cipro-
ﬂoxacin at the time of HCT compared with 42 patients
(53.2%) in the control group. Donor and recipent CMV status
were negative in 75% of patients with PC compare to 35.4% in
patients with severe GVHD without PC. The median time of
onset for acute GVHD was 64 days in the PC cohort (84 days
control group). The median time for PC development was
199 days from HCT. Stem cell donors were female in 72.7% of
patients with PC (47.3% in the control cohort). Sexemismatch
between donor and recipient was present in 50%, (26% in the
control group). 92% of patients received peripheral blood as
their source of stem cells (82.2% in the no PC cohort). HLA
disparity was present in 33.2% of patients with PC (15.2% in
the no PC cohort). 41.7% of patients developed GI tract
infections before the onset of PC (29.1% control group).
All patients were on calcineurin inhibitors at time of acute
GVHD onset. Treatment of aGVHD consisted of corticoste-
roids MP 2 mg/kg in 91.7% of PC cohort (65.8% in the control
group). The succcessive lines of treatment were: MMF 66.7%
(78.5% in the rest of the cohort), daclizumab 75% (34.2% in
the control group) and pentostatin 41.7.4% (5% in the no PC
cohort) with complete resolution of GVHD symptoms in
16.7% (32.9% in the rest of the cohort).
PC is a severe complication of early onset GI GVHD. Risk
factors included HLA disparity between donor and recipient,
female donor, high dose and prolongued corticosteroids
treatment for GVHD. GI tract infection may contribute to itspathophysiology and frequently preceeded PC onset. Anti-
bioprophylaxis with ciproﬂoxacin was a statistically signiﬁ-
cant risk factor for PC development. Oral cipro for GI tract
decontamination is suboptimal and should be revised.
Treatment of GI GVHD with daclizumab or pentostation
increase PC risk. CMV seronegatvity was not protective.
GVHD related PC is associated to a highmortality rate (75% in
the PC cohort and 59% no PC group) not statistically different
from the dismal outcome of steroid refractory aGVHD.449
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Background: Serositis and pericarditis are rare manifesta-
tions of chronic GVHD. No risk factors or predictive
biomarkers associated with this syndrome have been
recognized to date, and outcomes have not been described in
large series.
Methods: In an effort to better characterize this condition,
we searched our institutional database of allogeneic HCT
occurring at OHSU between 1996-2012 for pts identiﬁed as
having serositis with or without pericarditis. We reviewed
clinicopathologic data to identify a cohort of patients who
clearly had this complication in association with chronic
GVHD. Laboratory studies from 1month prior to diagnosis, at
diagnosis, and 1 month post-diagnosis of serositis +/-peri-
carditis, as well as outcomes from invasive procedures, were
included in our review.
Results: 894 allogeneic HCT procedures took place during
the study time frame. 23 cases were identiﬁed in the data-
base search, although 8 were not included in the ﬁnal
analysis (1 acute GVHD, 2 anasarca without clear serositis,
1 pre-transplant pericarditis, 1 malignant effusion, 3 HCT or
majority of care elsewhere). 15 met criteria for having
cGVHD-associated serositis or pericarditis: 14 were male pts,
and 10 received Cy/TBI conditioning. All but 1 pt had a prior
diagnosis of chronic GVHD. The complication occurred in the
setting of recent immunosuppression (IST) taper in 12 of the
cases. A signiﬁcant increase in bloodmonocytes (median 500
vs. 1000 cells/uLP ¼ .002) and decrease in serum albumin
(median 3.4 vs. 2.65,P ¼ .005) were identiﬁed at diagnosis
compared with those values at one month pre-diagnosis. 13
of 15 pts were treated with steroids, with 7 of those
demonstrating partial or complete response. 6 patients
required invasive interventions (1 periocardiocentesis, 3
pericardial windows, and 2 pericardial stripping) due to
severe symptoms. 3 pts died due to chronic GVHD
complications.
Conclusions: These data suggest that chronic GVHD-asso-
ciated serositis with or without pericarditis occurs mainly in
the setting of treated as opposed to de novo chronic GVHD,
frequently in the setting of IST taper. A notable predomi-
nance of male recipients receiving myeloablative TBI-based
conditioning were identiﬁed in this cohort. Biomarkers that
appear to be associated with the syndrome include
a decrease in albumin and an increase in absolute monocyte
count. Outcomes data from larger series are required to
better understand the role of invasive procedures and
optimal treatment for this rare complication.
